Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
HOUSTON, May 31, 2017 -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a corporate overview at the Jefferies 2017 Global Healthcare Conference on Wednesday, June 7 at 2:00 p.m. EDT in New York, NY.
A live webcast of the presentation may be accessed from the News & Events section of the Bellicum website. An archived version of the webcast will be available for replay for at least two weeks following the event.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.
Investors: Bellicum Pharmaceuticals Alan Musso, CFO 832-384-1116 [email protected] Media: BMC Communications Brad Miles 646-513-3125 [email protected]
